Caristo Diagnostics, a global leader in AI-powered technologies for cardiovascular disease, today announced that it has been selected as a 2026 Technology Pioneer by the World Economic Forum. The recognition places Caristo among 100 early-stage businesses from 23 countries that are developing breakthrough technologies with the potential to transform industries and societies.
Caristo was recognised for its AI-powered CaRi-Heart® technology, a novel solution designed to detect hidden coronary inflammation on cardiac CT. By uncovering this previously invisible driver of cardiovascular disease, CaRi-Heart analysis helps clinicians understand the root cause and severity of coronary artery disease and provides a personalised 10-year risk of cardiovascular death.
“Being named a Technology Pioneer by the World Economic Forum is a tremendous honour for Caristo and a meaningful recognition of our mission to transform health outcomes for patients through science and innovation,” said Steve Deitsch, CEO of Caristo Diagnostics. “We are focused on closing the gap in early diagnosis and enabling more personalised treatment so that cardiovascular disease can be identified sooner, managed more precisely and prevented more effectively.”
“We are excited to welcome Caristo Diagnostics to the 2026 Technology Pioneers Community,” said Verena Kuhn, Head of Innovator Communities at the World Economic Forum. “The world needs impactful and forward-thinking innovation to solve critical global health challenges. We look forward to seeing how they will contribute their perspectives to the Forum’s initiatives over the next two years.”
As part of the 2026 Technology Pioneers cohort, Caristo will join a global community of innovators and leaders, working across AI, energy, health, manufacturing, space, and the bioeconomy to tackle some of the world’s most urgent and complex challenges.
Read Also: Ontinue Recognized for Redefining Security Operations in the Autonomous Threat Era
